Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) insider Jo Ann Beltramello sold 29,167 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $14.20, for a total transaction of $414,171.40. Following the sale, the insider now owns 112,166 shares in the company, valued at $1,592,757.20. The sale was disclosed in a filing with the SEC, which is available at this link.

Jo Ann Beltramello also recently made the following trade(s):

  • On Tuesday, February 19th, Jo Ann Beltramello sold 8,377 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $13.62, for a total transaction of $114,094.74.
  • On Friday, February 8th, Jo Ann Beltramello sold 472 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $11.52, for a total transaction of $5,437.44.

NASDAQ MNTA opened at $13.77 on Thursday. Momenta Pharmaceuticals, Inc. has a 1 year low of $9.55 and a 1 year high of $32.20. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -6.78 and a beta of 2.24.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its earnings results on Friday, February 22nd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.39. Momenta Pharmaceuticals had a negative net margin of 232.92% and a negative return on equity of 47.74%. The business had revenue of $42.80 million for the quarter, compared to analysts’ expectations of $17.11 million. During the same period in the prior year, the company posted $0.18 EPS. The business’s revenue for the quarter was down 33.7% compared to the same quarter last year. As a group, equities analysts anticipate that Momenta Pharmaceuticals, Inc. will post -1.71 earnings per share for the current fiscal year.

A number of analysts recently commented on MNTA shares. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Thursday, January 3rd. ValuEngine cut shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 27th. Cantor Fitzgerald reiterated a “hold” rating and issued a $16.00 target price on shares of Momenta Pharmaceuticals in a research note on Friday, February 22nd. BidaskClub cut shares of Momenta Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, January 12th. Finally, Stifel Nicolaus reiterated a “buy” rating on shares of Momenta Pharmaceuticals in a research note on Tuesday, January 8th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $22.03.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Louisiana State Employees Retirement System increased its holdings in shares of Momenta Pharmaceuticals by 4.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 36,004 shares of the biotechnology company’s stock worth $397,000 after buying an additional 1,504 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Momenta Pharmaceuticals by 41.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,880 shares of the biotechnology company’s stock worth $65,000 after buying an additional 1,723 shares during the last quarter. American International Group Inc. increased its holdings in shares of Momenta Pharmaceuticals by 3.3% in the 4th quarter. American International Group Inc. now owns 62,451 shares of the biotechnology company’s stock worth $689,000 after buying an additional 2,003 shares during the last quarter. Piedmont Investment Advisors Inc. increased its holdings in shares of Momenta Pharmaceuticals by 25.0% in the 4th quarter. Piedmont Investment Advisors Inc. now owns 22,522 shares of the biotechnology company’s stock worth $249,000 after buying an additional 4,511 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its holdings in shares of Momenta Pharmaceuticals by 25.6% in the 4th quarter. State of Alaska Department of Revenue now owns 32,101 shares of the biotechnology company’s stock worth $354,000 after buying an additional 6,547 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2019/03/21/jo-ann-beltramello-sells-29167-shares-of-momenta-pharmaceuticals-inc-mnta-stock.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Featured Article: How is an ETF different from a mutual fund?

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.